Repligen Corporation — Third Quarter 2026 Earnings Summary

Repligen Corporation reported third-quarter 2026 revenue of $209.3 million, representing an 11% year-over-year increase as reported and 12.5% organic growth. The company closed its acquisition of BioLife Solutions in October 2026, a move intended to strengthen its position in the cell therapy market, and subsequently raised its full-year 2026 revenue guidance to a range of $844 million to $852 million. While GAAP results showed a loss from operations of $29.5 million driven by a significant intangible asset impairment charge, adjusted income from operations reached $33.3 million with adjusted earnings per share of $0.53. Additionally, the company announced the opening of a new Repligen Training & Innovation Center in Seoul, South Korea, to support its strategic expansion in the region.